
    
      This is a randomized (study medication assigned to participants by chance), open-label,
      multi-centric (conducted in more than one center) and 2-arm flexible-dose monotherapy study
      of topiramate compared with 1 another AED (levetiracetam) in pediatric participants with
      epilepsy. The total study duration will be up to of 1 year and 2 months per participant. The
      study consists of 3 parts: Screening (that is, up to 35 days before study commences on Day
      1); Treatment (1 year) and post-treatment (30 days). Safety will primarily be evaluated by
      percentage of participants with kidney stones and change from baseline in bone mineral
      density at Month 12.
    
  